• Milestone Pharmaceuticals posted a net loss of $28.61 million for the quarter ended June 30, 2026, worsening 120.7% year over year.
• Revenue turned to $559,000, driven by CARDAMYST product sales; no revenue was recorded a year earlier.
• Selling, general and administrative costs climbed 155.6% to $22.65 million, due to personnel, professional, and launch-related operational spending for CARDAMYST.
• Research and development expense edged down 4.4% to $3.51 million, while interest expense jumped 396.9% to $4.73 million.
• Cash and cash equivalents totaled $169.7 million at June 30, 2026; the company expects funding to cover at least 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Milestone Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-094435), on August 12, 2026, and is solely responsible for the information contained therein.